Skip to content
GeoClinicalTrials
Back to search

NCT06466382Recruiting

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

Official recordSimplified version

Summary

The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.

Inclusion criteria

• Age ≥ 18 years • Newly diagnosed EOC (adenocarcinoma of the ovary, peritoneum, and fallopian tube) and carcinosarcoma patients with a suspected FIGO Stage III and IV • No immediate need of systemic or surgical treatment at time of and until 2 weeks after diagnosis • Envisaged surgical candidate for interval debulking after 2 cycles of treatment • Patients have adequate hematology, liver and kidney functions • Willing and able to attend the visits, to understand the purpose of the trial and all trial-related procedures • ECOG 0-2 • Written informed consent according to national legal and regulatory requirements prior to any project specific procedures

Exclusion criteria

• ECOG ≥3 • Pregnant or lactating women • Any other malignancy within the last 5 years which has an impact on the prognosis of the patient • Concurrent participation in another clinical trial on the same indication • Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the sponsor-project leader may interfere with the project or affect patient compliance

Contacts

The trial team's contact details are shown on request.

See the official trial record
Status
Recruiting
Phase
No phase (N/A)
Study type
Interventional
Countries
Switzerland
Sponsor
Swiss GO Trial Group(Network / cooperative)
Protocol no.
Swiss-GO-08/ OV Precision
Conditions
Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Ovarian Endometrioid Carcinoma, High-grade Serous Ovarian Carcinoma (HGSOC)
Interventions
Other, Drug

Treatments studied

  • Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling
  • Carboplatin / Paclitaxel Chemotherapy

Collaborators

Tumor Profiler Center Switzerland

Locations · 9

  • Baden, SwitzerlandKantonsspital Baden AGRecruiting at this site
  • Basel, SwitzerlandUniversitätsspital BaselRecruiting at this site
  • Sankt Gallen, SwitzerlandHOCH Health Ostschweiz Kantonsspital St.GallenRecruiting at this site
  • Frauenfeld, SwitzerlandThurgau AG Frauenfeld / MünsterlingenRecruiting at this site
  • Bern, SwitzerlandInselspital Bern (University Hospital for Medical Oncology)Recruiting at this site
  • Fribourg, SwitzerlandHFR-Fribourg- Hopital CantonalRecruiting at this site
  • Lucerne, SwitzerlandHirslanden Klinik St. AnnaRecruiting at this site
  • Winterthur, SwitzerlandKantonsspital WinterthurRecruiting at this site
  • Zurich, SwitzerlandUniversity Hospital ZurichRecruiting at this site

In total, worldwide, 9 of the 10 sites listed in the registry are recruiting; the other one is not currently recruiting.

Site status per the ClinicalTrials.gov registry (last update posted: October 27, 2026).

This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.

See also

Other versions

These results are indicative and do not replace medical advice — discuss them with your doctor.